DS3790 / Daiichi Sankyo - LARVOL DELTA

DS3790-076: A First-in-Human Trial of DS3790a in Participants with Hematological Malignancies. (clinicaltrialsregister.eu) - P1/2 | N=30 | Not yet recruiting | Sponsor: Daiichi Sankyo Inc.

First-in-human • New P1/2 trial • Hematological Malignancies • Oncology

The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. (Businesswire) - "The trial is expected to enroll approximately 420 patients across multiple sites globally, including Asia, Europe and North America."

First-in-human • Trial status • Non-Hodgkin’s Lymphoma

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=420 | Recruiting | Sponsor: Daiichi Sankyo | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Hematological Malignancies • Oncology